Drugs in Dev.
Trauma (Emergency, Injury, Surgery)
Phase II
Denmark 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PAT-1251
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Pharmakea therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Galecto to merge with onetime Celgene partner PharmAkea
Details : The two firms will combine & put in robust fibrosis and cancer services, including a recently inhaled galectin-3 modulator ph IIb for the potential treatment of idiopathic pulmonary fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 07, 2020
Lead Product(s) : PAT-1251
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Pharmakea therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
